Wedbush restated their outperform rating on shares of Bluebird Bio Inc. (NASDAQ:BLUE) in a research note released on Wednesday morning. They currently have a $95.00 price target on the stock.
Several other analysts also recently commented on the company. Roth Capital initiated coverage on Bluebird Bio in a research note on Thursday, September 22nd. They set a buy rating and a $87.00 price objective on the stock. Goldman Sachs Group Inc. raised Bluebird Bio from a buy rating to a conviction-buy rating and set a $135.00 price objective on the stock in a research note on Thursday, September 15th. Cantor Fitzgerald downgraded Bluebird Bio from a hold rating to a sell rating and dropped their price objective for the stock from $65.24 to $37.00 in a research note on Friday, October 14th. Leerink Swann raised their price objective on Bluebird Bio from $67.00 to $80.00 and gave the stock an outperform rating in a research note on Friday, October 14th. Finally, Maxim Group reaffirmed a buy rating and set a $85.00 price objective (down previously from $105.00) on shares of Bluebird Bio in a research note on Thursday, August 4th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have given a buy rating to the stock. Bluebird Bio currently has an average rating of Buy and an average target price of $82.82.
Shares of Bluebird Bio (NASDAQ:BLUE) opened at 60.65 on Wednesday. Bluebird Bio has a 12 month low of $35.37 and a 12 month high of $90.01. The firm’s market cap is $2.26 billion. The firm has a 50 day moving average price of $55.97 and a 200-day moving average price of $53.04.
Bluebird Bio (NASDAQ:BLUE) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported ($2.07) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.59) by $0.48. The business had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.82 million. Bluebird Bio had a negative return on equity of 30.79% and a negative net margin of 3,941.72%. The business’s quarterly revenue was up 17.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.18) EPS. On average, analysts predict that Bluebird Bio will post ($7.05) EPS for the current fiscal year.
In other Bluebird Bio news, insider Eric Sullivan sold 416 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $67.00, for a total transaction of $27,872.00. Following the completion of the sale, the insider now directly owns 5,891 shares in the company, valued at $394,697. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 3.50% of the company’s stock.
Large investors have recently modified their holdings of the company. First Mercantile Trust Co. bought a new stake in shares of Bluebird Bio during the third quarter valued at about $129,000. Sei Investments Co. increased its stake in shares of Bluebird Bio by 106.7% in the third quarter. Sei Investments Co. now owns 2,515 shares of the company’s stock valued at $170,000 after buying an additional 1,298 shares during the period. Seven Eight Capital LLC bought a new stake in shares of Bluebird Bio during the first quarter valued at about $108,000. Winslow Evans & Crocker Inc. increased its stake in shares of Bluebird Bio by 170.0% in the third quarter. Winslow Evans & Crocker Inc. now owns 2,700 shares of the company’s stock valued at $183,000 after buying an additional 1,700 shares during the period. Finally, Advisor Group Inc. increased its stake in shares of Bluebird Bio by 482.2% in the third quarter. Advisor Group Inc. now owns 2,783 shares of the company’s stock valued at $188,000 after buying an additional 2,305 shares during the period.
Bluebird Bio Company Profile